Wound Care

Summarizing EWMA in Madrid

От кого: Mölnlycke Health Care, июня 4 2014Опубликованные в: Wound Care

As in previous years, delegates who attended the EWMA 2014 Conference in Madrid left much wiser from the experience. The wound management clinics they’ll return to will be richer in terms of the new knowledge gained, the new techniques and ways of thinking learned and for the new contacts which were made.

We at Mölnlycke Health Care would like to thank all of our customers as well as the visitors who came to our booth. All of you left with a greater understanding of how dressings with Safetac® minimises pain, trauma to the wound and damage to the surrounding skin when used on a variety of wound types such as venous leg ulcers, diabetic foot ulcers and pressure ulcers1,2,3,4,5. You also learnt how Mepilex® Border can help to reduce the incidence of pressure ulcers when used as an adjunct to standard preventive measures6, how Mepitel® Film is able to prevent radiotherapy-induced skin reactions7 and how Mepilex® Ag helps to reduce the cost of burns treatment8. Many delegates showed a great interest in our Avance® NPWT system with Safetac® technology. Plus we were able to demonstrate our new WoundEL® electro stimulation system and show you how it supports wound care managers treating hard-to-heal chronic wounds with less pain9.

The knowledge imparted in our sponsored symposium – ‘Influencing cost effective wound care’ – was also very well received. The need to shift the cost containment focus from per unit to a more holistic approach was discussed in-depth, as well as some new work on the cost of dressing-related trauma in chronic wounds such as Diabetic Foot Ulcers. A review of the evidence showed that pressure ulcer prevention is more cost effective than pressure ulcer treatment10. Overall several different scenarios were discussed where costs can be reduced and the overall quality of care can be increased simultaneously. With current topics such as these open for discussion, it was no surprise that every single seat in the auditorium was taken!

Once again, thank you for helping us make EWMA 2014 in Madrid such a great event!

 

References

  1. White, R. A multinational survey of the assessment of pain when removing dressings. Wounds UK 2008;4(1):14-22.
  2. Meuleneire, F., Fostier, A. Local treatment of heel pressure ulcers with a silicone foam dressing. Poster presentation at the 3rd World Union of Wound Healing Societies, Toronto, Canada, 2008.
  3. Upton, D., Solowiej, K. The impact of atraumatic vs conventional dressings on pain and stress. Journal of Wound Care 2012 21(5):209-215.
  4. Waring, M., et al. An evaluation of the skin stripping ofwound dressing adhesives. Journal of Wound Care 2011;20(9):412-422.
  5. Meaume, S., et al. A study to compare a new-self-adherent soft silicone dressing with a self-adherent polymer dressing in stage II pressure ulcers. Ostomy Wound Management 2003;49(9):44-51.
  6. Santamaria., N et al A randomised controlled trial of the effectiveness of soft silicone multi-layered foam dressings in the prevention of sacral and heel pressure ulcers in trauma and critically ill patients: the border trial. International Wound Journal 2013; doi: 10.1111/iwj.12101.
  7. Herst, P.M., et al. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiotherapy and Oncology 2014, Jan 29 {Epub ahead of print}
  8. Silverstein, P., et al. An open parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam. Journal of Burn Care and Research 2011;32(6):627-626.
  9. Leloup, P., et al. The analgesic effect of electrostimulation (WoundEL) in the treatment of leg ulcers. International Wound Journal 2014;doi:10/1111/iwj.12211.
  10. Santamaria, N., et al. The cost-benefit of using soft silicone multilayered foam dressings to prevent sacral and heel pressure ulcers in trauma and critically ill patients: a within-trial analysis of the Border Trial. International Wound Journal 2013; Oct 6. doi: 10.1111/iwj.12160

 

Поделиться